Lifebit

Lifebit Biotech Ltd specializes in advanced genomics and health data solutions, offering innovative software designed to enhance the access and analysis of biomedical data across multiple sectors. Founded in 2017, Lifebit Biotech Ltd is based in London, UK, and focuses on providing solutions for biomedical data analysis. The company was co-founded by Maria Dunford and Pablo Barja, with Dunford currently serving as CEO. Lifebit has successfully completed a total of 4 investment deals, with the latest round being a Series B funding of GBP 43.

70 million led by Tiger Global Management on August 27, 2021. The company has raised a total of GBP 43. 70 million, resulting in a current valuation of GBP 242. 33 million.

Lifebit provides advanced genomics and health data software solutions designed to facilitate the secure access and analysis of biomedical data across various sectors. Their core product offerings include the Trusted Data Marketplace™ (TDM), which allows users to access a vast network of real-world biomedical data; the Trusted Data Lakehouse (TDL), which harmonizes and organizes clinico-genomic data; and the Trusted Research Environment (TRE), enabling collaborative and secure research. These solutions target a multitude of use cases, such as accelerating drug discovery, enhancing clinical interpretation, and enabling population-scale analyses. Lifebit serves a diverse client base that comprises research institutions, healthcare organizations, and pharmaceutical companies across multiple geographical markets, including Europe, North America, and Asia, with a strong emphasis on the United Kingdom, the United States, and Singapore.

Lifebit’s revenue model is structured primarily around B2B transactions, focusing on subscriptions and partnerships with various organizations in the healthcare and life sciences sectors. Clients typically engage with Lifebit through contractual agreements that outline access to their proprietary software solutions, such as the NF-Copilot for Nextflow pipeline enhancement or the federated data solutions for secure data analysis. Pricing structures are tailored to the specific needs of clients, including possibly tiered subscription models based on the extent of data usage and the number of users accessing the platform. Given Lifebit’s collaborative emphasis, transactions often involve long-term partnerships that allow clients to integrate the company's solutions into their research workflows, optimizing both data accessibility and analysis capabilities.

In August 2021, Lifebit Biotech Ltd raised GBP 43. 70 million in Series B funding led by Tiger Global Management, with participation from Beacon Capital, Eurazeo, and Pentech Ventures. The funding will be allocated towards global expansion, with a focus on enhancing customer success and accelerating team growth. The company plans to launch new products aimed at improving their software offerings and is actively pursuing expansion into new geographic markets.

Specific target markets include Europe, North America, and Asia.